Efficacy and safety of human umbilical cord-derived mesenchymal stem cells versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-host disease: a multicentre, randomized, double-blind, phase 2 trial
Authors
Mingzhe Han (ORCID: https://orcid.org/0000-0002-4911-6093)
Efficacy and safety of human umbilical cord-derived mesenchymal stem cells versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-host disease: a multicentre, randomized, double-blind, phase 2 trial
Mingzhe Han, Xiaoqiang Hou, Erlie Jiang, Chen Yao et al.
Citations
19 citations
Journal
BMC Medicine
Topics
Mesenchymal stem cell research
Field-Weighted Citation Impact (FWCI)
8.32
article
Efficacy and safety of human umbilical cord-derived mesenchymal stem cells versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-host disease: a multicentre, randomized, double-blind, phase 2 trial
Mingzhe Han, Xiaoqiang Hou, Erlie Jiang, Chen Yao, Kun Qian, Donglin Yang, Yang-Liu Shao, Lu Wang, Yuhang Li, Daihong Liu, Liangding Hu
article en
19 citations
Abstract
No abstract available for this paper.
Publication Tag
BMC MedicineVol. 22(1)
Institutions
Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Peking University (CN), Nankai University (CN), Chinese PLA General Hospital (CN), Peking University First Hospital (CN), Platinum Group Coatings (United States) (US), Institute of Hematology & Blood Diseases Hospital (CN)